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Abstract
Background: TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I
inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-
gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric
or gastro-oesophageal junction (GOJ) adenocarcinomas.
Methods: Eligible patients had metastatic or locally advanced gastric or Siewert Types II or III GOJ inoperable
adenocarcinoma. Patients were chemotherapy naïve unless this had been administered in the perioperative setting.
TP300 was administered as a 1-h intravenous infusion every 3 weeks (a cycle) for up to 6 cycles at a starting dose
of 8 mg/m2 with intra-patient escalation to 10 mg/m2 from cycle 2 in the absence of dose-limiting toxicity. Tumour
responses (RECIST 1.1) were assessed every 6 weeks. Toxicity was recorded by NCI-CTCAE version 3.0. Using a
modified two-stage Simon design (Stage I and II), a total of 43 patients were to be included providing there were 3
of 18 patients with objective response in Stage I of the study.
Results: In Stage I of the study 20 patients (14 males, 6 females), median age 67 years (range 40 − 82), performance
status ECOG 0/1, with GC [14] or GOJ carcinoma [6] were enrolled. Of the 16 evaluable patients, 11 received the
planned dose increase to 10 mg/m2 at cycle 2, 2 decreased to 6 mg/m2, and 3 continued on 8 mg/m2. There were
no objective responses after 2 cycles of treatment. Twelve patients had stable disease for 1 − 5 months and 4 had
progressive disease. Median progression free survival (PFS) was 4.1 months (CI [1.6 − 4.9]), median time to
progression (TTP) was 2.9 months (CI [1.4 − 4.2]). Grade 3/4 toxicities (worst grade all cycles) included 7 patients
(35 %) with neutropenia, 4 patients (20 %) with anaemia, 2 patients (10 %) with thrombocytopenia, and 3 patients
(15 %) with fatigue.
This study was terminated at the end of Stage I due to a lack of the required (3/18) responders.
Conclusions: This study of TP300 showed good drug tolerability but it failed to demonstrate sufficient efficacy as
measured by radiological response.
Trial registration: EU-CTR 2009-012097-12 2009-09-03
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Background
Inhibition of topoisomerase-I (Topo-1) is a clinically ef-
fective treatment strategy for many patients with cancer
[1]. Irinotecan hydrochloride is the most widely used
Topo-1 inhibitor with activity against a wide range of
cancers (e.g. colorectal, glioma, oesophageal, gastric,
non-small cell lung and pancreatic cancers), either as a
single agent or in combination [2–5]. Irinotecan has,
however, a number of properties that limit its usefulness.
It is metabolized enzymatically by carboxylesterase 2
(CES2), predominantly within the liver, to SN-38 (a sig-
nificantly more potent Topo-1 inhibitor). This conver-
sion shows considerable inter-individual variability,
resulting in a wide range of systemic SN-38 exposure for
a given dose that may influence the efficacy and toxicity
of irinotecan. Clinically, the use of irinotecan can be lim-
ited by diarrhoea and neutropenia, with potential impact
on dose intensity, as well as patient acceptability. Low
activity of the SN-38 metabolising enzyme UGT1A1 is
associated with an increased risk of diarrhoea and mye-
losuppression [5], and in 2005 the US FDA recom-
mended irinotecan dosing be modified in patients
carrying the UGT1A1*28 polymorphism [2, 6]. The de-
velopment of Topo-1 inhibitors not subject to such
pharmacogenomic variability might, therefore, enhance
the clinical efficacy and utility of this class of agents.
TP300 (glycine,glycyl-N-methyl-,(9S)-9-ethyl-9,10,13,15-
tetrahydro-10,13-dioxo-1-pentyl-1H,12H-pyrano[3'',4'':6',7']
indolizino[2',1':5,6]pyrido[4,3,2-de]quinazolin-9-yl ester,
hydrochloride) has been developed as a water soluble
prodrug of the Topo-1 inhibitor TP3076, and its active
metabolite, TP3011, both of which are equipotent to
SN-38 in terms of Topo-1 inhibition [7] (Fig. 1). TP300
has activity at nanomolar concentrations across a range
of tumour types in vitro and, unlike SN-38, appears
active in tumours over-expressing the breast cancer
resistance protein [BCRP] [7]. In man, TP300 is con-
verted non-enzymatically to TP3076, then metabolized
to TP3011 by aldehyde oxidase 1 in liver. TP3011
metabolite and TP3076 are equipotent as Topo-1 inhibi-
tors, with an IC50 in the sub-nanomolar range [8]. Im-
portantly, TP3076 lacks the phenolic-OH group required
for glucuronidation so should not be influenced signifi-
cantly by polymorphisms in the UGT1A1 gene. It is pos-
tulated that this will result in less variation in activation
and toxicity with TP300 than with irinotecan; specific-
ally, it would not be expected to cause severe diarrhoea.
In preclinical models TP300 has superior anti-tumour
activity and a wider therapeutic index than CPT-11 in
various tumour types, including gastric cancer [8]. Fur-
thermore TP300 showed additive or synergistic antitu-
mor effects in combination with other anti-cancer drugs
such as capecitabine, oxaliplatin, cisplatin, bevacizumab
and cetuximab.
A Phase I study of TP300 was performed in patients
with chemotherapy insensitive or refractory tumours [9].
TP300 had predictable hematologic toxicity, and diar-
rhoea was uncommon. AUC at MTD was substantially
greater than for SN-38. TP3076 and TP3011 are equipo-
tent with SN-38, suggesting a pharmacokinetic advan-
tage. Pharmacologically, it was confirmed that TP300
was 100 % transformed to its active form (TP3076) and
rapidly and extensively converted to an active metabolite
(TP3011). There was a linear relationship between AUC
and dose, up to 10 mg/m2 and AUC was not affected by
UGT1A1 or aldehyde oxidase genotype.
Topoisomerase I inhibitors such as irinotecan have
shown activity in the treatment of gastric cancer, with
single agent irinotecan demonstrating a response rate of
23 %. Phase II studies in patients with gastric cancer
have demonstrated single-agent response rates of ap-
proximately 20 % for a number of chemotherapeutic
agents including irinotecan [10].
Gastric cancer is one of the most common malignant
diseases worldwide. The prognosis of this aggressive
tumour is poor, even when detected in the early stages
and treated by radical resection [11]. In most cases, me-
tastases are already present at the time of diagnosis.
Fig. 1 The fate of TP300, active form (TP3076) and its metabolite (TP3011)
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Compared to purely supportive treatment, systemic
chemotherapy leads to a significant extension of survival
and clear improvement in the quality of life with respect
to the reduction of tumour-related symptoms. This was
demonstrated in various randomized studies [12–18].
However, objective remissions are often only short-
term, most patients die of the disease within 1 year and
response to chemotherapy does not always translate into
improvement in survival. The tumours respond to treat-
ment, but quickly become resistant. It is therefore neces-
sary to search for new substances and more effective
therapies are clearly needed for patients with metastatic
gastric cancer.
Several drugs, when used as single agents, have been
associated with a reduction of more than 50 % in meas-
urable tumour mass (i.e. an “objective response” in over
15 % of patients). Topoisomerase I inhibitors such as iri-
notecan have shown activity in the treatment of gastric
cancer, with single agent irinotecan demonstrating a re-
sponse rate of 23 %. Fluorouracil, which has been exam-
ined most extensively, produces a response rate of
approximately 20 % [19]. However, complete responses
with single agents are rare and partial regressions have
been relatively brief. In addition, reduction in toxicity
and better tolerance are important for gastric cancer pa-
tients. This “window of opportunity” phase II study was
performed to evaluate the antitumour activity of TP300
in patients with advanced gastric or oesophago-gastric
junction adenocarcinoma, receiving first-line chemother-
apy without exposure to prior systemic chemotherapy
for advanced disease. This study was a modified Simon’s
two stage design [20].
Methods
Study design
Open-label, non-randomised, multi-centre study to
evaluate the anti-tumour activity of TP300 in previously
untreated patients with advanced gastric and/or gastro-
oesophageal junction adenocarcinoma. The study com-
plied with Good Clinical Practice and the Declaration of
Helsinki, and was approved by research ethics commit-
tees in all institutions prior to initiation. All patients
gave written informed consent for the clinical study and
separately for the genotype/biomarker study before
undergoing any study-related procedures.
The primary objective of this study was to determine
the objective response rate (ORR) of TP300 in patients
with untreated advanced gastric or gastro-oesophageal
junction adenocarcinoma. The secondary objectives were
to determine the time to progression (TTP) and progres-
sion free survival (PFS), to determine the safety of
TP300 and to further evaluate the PK profile of TP300
evaluating any PK/PD correlation.
Patients and eligibility criteria
Eligible patients had metastatic or locally advanced gas-
tric or Siewert Types II or III GOJ inoperable adenocar-
cinoma. The patients were previously untreated with
chemotherapy unless this had been administered in the
perioperative setting, were ≥ 18 years old, with one or
more measurable target lesions as defined by RECIST
version 1.1, and had an Eastern Cooperative Oncology
Group performance status of 1 or less.
Other inclusion criteria included adequate bone mar-
row function (neutrophil count ≥ 1.0 × 109, platelet
count ≥ 100 × 109, and haemoglobin ≥9 g/dL) and ad-
equate hepatic (serum bilirubin ≤ 1.5 x upper limit of
normal [ULN], alanine amino transferase (ALT) and as-
partate amino transferase (AST) ≤ 2.5 x ULN) and renal
(serum creatinine ≤ 1.5 x ULN) function.
A history of severe or life-threatening drug allergy or
hypersensitivity to camptothecin derivatives and diar-
rhoea (excess of 2-3 stools/day above normal frequency
within 2 weeks prior to the start of the study) were ex-
clusion criteria.
Treatment and dose escalation
TP300 was administered as a 1-h intravenous (i.v.) infu-
sion every 3 weeks (one cycle), for up to 6 cycles. The
starting dose of TP300 was 8 mg/m2 in cycle 1. From cycle
2 onwards the dose was increased, where possible, to
10 mg/m2 in the absence of DLT but for some patients
the dose was not changed or was lowered. This was to
minimize the risk of serious toxicity. At the discretion of
the investigator the treatment could be continued beyond
cycle 6 if in the best interests of the patient.
Evaluation of efficacy
Patients who received at least 2 cycles of TP300 and had
at least 1 post-baseline tumour assessment were evaluable
for assessment of response. After the baseline evaluation,
tumours were assessed every 2 cycles using the Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Responses were assessed by local investigators and by an
independent radiologic review committee (IRC).
Evaluation of toxicity
Toxicity was assessed weekly and graded using the Na-
tional Cancer Institute Common Toxicity Criteria
(CTCAE) version 3.0. DLT was defined as the occur-
rence of any of the following adverse events: grade 4
thrombocytopenia; febrile neutropenia or grade 4 neu-
tropenia > 5 days duration; grade 4 diarrhoea not re-
duced to grade 1 within 2 days of appropriate therapy;
other gastro-intestinal toxicities (e.g. vomiting, nausea,
stomatitis) ≥ grade 3 and not reduced to grade 1 within
2 days of appropriate therapy; any other non-
hematologic toxicities ≥ grade 3 (excluding alopecia).
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Statistical analysis
An optimal two-stage design was used where the esti-
mated response rate was 25 % and the null hypothesis
response rate was 10 % or less [20]. The study was cal-
culated to have a one-sided α-error of 5 % and a power
of 80 %. Under these assumptions, 18 evaluable patients
were to be treated in stage 1 of the study. At least three
responses were required to continue to stage 2 where an
additional 25 evaluable patients would be treated (up to
a total of 43). Overall, if a total of eight responses or
more were observed, the drug would be considered
active.
Evaluation of pharmacokinetics
Blood samples for PK analysis were collected from each
subject at 4 time points (pre dose, then 1, 5, and 24 h
after the start of drug administration) in cycles 1 and 2.
In brief, samples were processed by extraction of protein
using addition of organic solvent containing internal
standards. Samples were then directly injected into an
LC-MS/MS system (Ionization: ESI positive, Mode:
MRM). The lower limits of quantification of TP3076
and TP3011 in human plasma were 40 pg/mL, with the
precisions being 7.1 to 12.1 % and 8.0 to 11.4 %,
respectively.
Results
Patient characteristics
Twenty patients were enrolled into the study from 6 UK
Centres between October 2009 and November 2010.
One patient did not receive the study medication be-
cause of out of range pre-first dose blood results. Nine-
teen patients received the study medication, but one
patient did not complete 2 cycles of treatment and could
not be evaluated for tumour response. Eighteen patients
received at least 2 cycles of treatment and were evalu-
able for tumour response.
Two of the 18 patients were deemed non-evaluable by
the IRC due to the absence of an evaluable target lesion.
Therefore 16 patients were included in the efficacy
evaluation. Of 16 evaluable patients, 6 completed 2 cy-
cles, 2 received 3 cycles, 3 received 4 cycles and 5 pa-
tients completed 6 cycles of treatment. Five patients did
not receive dose escalation from 8 mg/m2 at cycle 1 to
10 mg/m2 in subsequent cycles. The median number of
treatment cycles was 3. A summary of patient demo-
graphic characteristics is given in Table 1.
Pharmacokinetics
Plasma mean (S.D.) drug concentration of unchanged
drug and active metabolite in cycles 1 and 2 at 24 h after
administration were 1.82 (5.85), 0.809 (0.635) and
5.39 ng/mL, respectively. The pharmacokinetics were
similar to that established in the Phase I study [9].
Efficacy
The tumour assessments were performed by investiga-
tive sites and the IRC. Although there were some differ-
ences between the two assessments, these were deemed
within acceptable limits and the efficacy analysis was
based on the IRC assessment.
Of the 16 evaluable patients, no patients had a
complete or partial response, 12 had stable disease, as
their best response, for 1-5 months, and the other 4
Table 1 Demographic and baseline characteristics (Safety
Population)
TP300
N = 19
Sex
Male 13 (68 %)
Female 6 (32 %)
Race
Caucasian 19 (100 %)
Age in years
Mean 66.1
SD 9.26
Median 67.0
Min-Max 40–82
Age (years)
< 65 7 (37 %)
> =65 12 (63 %)
Duration from First Diag. to Dose in Days
Median 53.0
Min-Max 33–3648
Diagnosis
Gastric Adenocarcinoma 13 (68 %)
Gastro-oesophageal Junction Adenocarcinoma: Type II 4 (21 %)
Gastro-oesophageal Junction Adenocarcinoma: Type II 2 (11 %)
ECOG Performance Status
0 12 (63 %)
1 7 (37 %)
Prior Surgery
No 13 (68 %)
Yes 6 (32 %)
Prior Radiotherapy
No 19 (100 %)
Prior Neoadjuvant Chemotherapy
No 17 (89 %)
Yes 2 (11 %)
Prior Adjuvant Chemotherapy
No 16 (84 %)
Yes 3 (16 %)
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patients had progressive disease after cycle 2. A sum-
mary of the best overall response is shown in Table 2.
Eight events of progression, including one death oc-
curred, and the median PFS was 4.1 months (CI [1.6–4.9
and the median TTP was 2.9 months (CI [1.4–4.2])
(Fig. 2).
Toxicity
Diarrhoea, if it occurred, was grade 1-2 and of short dur-
ation. Grade 3-4 haematological toxicity was observed at
a frequency similar to that of other cytotoxic agents with
similar mode of action.
There was one case of gastrointestinal perforation, asso-
ciated with a toxic death (grade 5). Overall there were 26
drug - related grade 3-4 AEs. Four patients experienced
grade 4, and three patients grade 3 neutropenia. One pa-
tient experienced grade 3 and one patient grade 4 throbm-
bocytopaenia. One patient had grade 3 neutropenic sepsis
which lasted 4 days and the dose of TP300 was subse-
quently reduced to 6 mg/m2. All haematological toxicities
resolved. Among the grade 3-4 non-haematological toxic-
ities, fatigue was the commonest (3 events of grade 3 in-
tensity). There were 3 related grade 3-5 gastrointestinal
events. The events of abdominal pain (grade 4), distension
(grade 3) and perforation (grade 5) occurred in the same
patient who had only received 1 cycle of 8 mg/m2.
Out of 10 DLTs, 3 occurred at doses less than 10 mg/
m2; 2 of these were thrombocytopenia grade 4 and
neutropenia grade 4 in patients treated with 8 mg/m2. In
both cases the dose was reduced to 6 mg/m2 without re-
currence of the toxicity. The other DLT, at 8 mg/m2, oc-
curred in a patient who received one dose of TP300
before presenting with a serious adverse event of gastro-
intestinal perforation with a fatal outcome. This event
was deemed to be of low possible causality in relation to
study drug TP300, since this patient had a pre-existing
gastric ulcer. The remaining 7 DLTs, all at the 10 mg/m2
dose level, were grade 3 or 4 in intensity and except for
the fatigue (which remained unresolved), resolved with
either minor or no sequelae. In all these patients, subse-
quent doses of TP300 were reduced for the rest of the
treatment cycles.
Discussion
The dose chosen for this proof of concept study was the
MTD in the Phase I study – on a three-weekly adminis-
tration schedule. Although the MTD was defined at
10 mg/m2, and this was tolerable, the frequency of grade
3 neutropenia at this dose suggested it would be safer
for patients to start on a dose of 8 mg/m2 for one cycle
before escalating to 10 mg/m2 if well-tolerated. Four pa-
tients remained on 8 mg/m2, with no dose escalation,
and 2 had a reduction to a lower dose after cycle 1, but
overall it was considered that this was the correct dosing
strategy.
The safety profile seen in the study was as anticipated
from the phase I study. A significant number of patients
developed haematological toxicity (37 % with grade 3 or
4 neutropenia), suggesting adequate dosing. Furthermore
population PK-PD modelling from the phase I study in-
dicated that the decrease in ANC following treatment
with TP300 fitted well with total concentrations of
TP3076 and TP3011 [21].
Other toxicities were similar to other topoisomerase I
inhibitors (alopecia, fatigue etc.), with the exception of
diarrhoea, which occurred less frequently than might
have been expected with treatment using 3 weekly irino-
tecan. This is in keeping with previous clinical and pre-
clinical studies of TP300.
Oesophago-gastric cancer response rates to single
agent cytotoxic first-line are around 18 % [3] and pa-
tients were carefully chosen, and monitored on this
study of an untried drug when a standard and reason-
ably effective combination treatment already existed.
Hence the selection criteria for study entry focussed on
those with a good performance status, low tumour bur-
den and a normal serum albumin (a reliable prognostic
factor), so that they were able to receive standard
chemotherapy subsequently on disease progression.
The study design, with optimum dosing determined by
tolerance of a dose lower than the Phase I defined MTD
in the first cycle is unlikely to have led to suboptimal
dosing. The fall in neutrophil count during cycle 1 (at
8 mg/m2) would support this. The small number of pa-
tients evaluated may have reduced the likelihood of de-
tecting a weak response. Irinotecan monotherapy has
shown response rates of 20 % in chemotherapy naïve pa-
tients with metastatic gastric cancer [13]. According to
the Simon’s two stage design, 3 or more responders out
of 18 evaluable patients at the interim analysis were
Table 2 Summary of Best Overall Response (CR + PR) by Study
Treatment (Assessed by Committee)
Evaluable patients 17
Complete Response 0
Partial Response 0
Stable Disease 12
Disease Progression 4
Not Evaluable 1
Overall Response Rate 0
Disease Control Rate 70.6 %
Evaluable Patients: The full analysis set (FAS) of 17 includes patients who received at
least one dose of TP300 and had at least one measurable target-lesion confirmed
by independent review committee (IRC)
Not Evaluable: 1 patient did not have a post dose tumour radiological
assessment, so could not be assessed
Note: A further 2 patients who received TP300 were excluded from the FAS, as
the target lesion/s could not be confirmed by IRC
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necessary to allow initiation of stage II of the study.
However, as no responders were seen amongst the 16
evaluable patients in stage I of the study it was not con-
sidered necessary to recruit further patients to achieve
the target 18, because it would not have been possible to
achieve 3 responding patients.
Examining the radiological responses in more detail, we
found that even among the patients with stable disease
there was wide variation in behaviour of the target lesions
with some certainly increasing in size during treatment.
There is insufficient information to confirm whether the
exposure to TP300 in the tumour was adequate. However,
we observed adequate evidence of a pharmacodynamic ef-
fect since there was significant bone marrow toxicity. The
three-weekly administration regimen used in Phase I was
carried into this study and, based on equivalent data from
irinotecan, may have been expected to produce a measur-
able anti-tumour effect. It may be, however, that more fre-
quent dosing (e.g. weekly), albeit with lower doses, would
have given more promising results. Based on the manage-
able nature of haematological effects and the relative in-
frequency of other serious adverse reactions, there may be
scope for pursuing higher tumour exposure by more fre-
quent dosing.
Conclusions
In conclusion, while this proof of concept study of
TP300 in patients with advanced gastric or gastro-
oesophageal cancer showed acceptable drug tolerability
and confirmed the stable pharmacokinetics established
in Phase I, and while there were cases of disease stabil-
isation for up to the maximum 6 cycles, it did not
achieve the required primary end-point efficacy, as mea-
sured by complete or partial radiological response.
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